

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 67112

Title: Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer

Reviewer's code: 05402718

Position: Peer Reviewer

Academic degree: PhD

Professional title: Assistant Professor, Research Associate

Reviewer's Country/Territory: China

Author's Country/Territory: Peru

Manuscript submission date: 2021-04-16

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-23 13:15

Reviewer performed review: 2021-05-03 09:41

Review time: 9 Days and 20 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

In the present study, Dr. Sotelo MJ et al. reviewed recent advances in the management of early EGFR-mutated NSCLC. Although there is some interesting, there are still some comments for the authors. 1. Except OS analysis, PFS and ORR also should be discussed. 2. I suggest authors add a figure to further describe how EGFR-mutated influence NSCLC. 3. Authors discuss that Adjuvant treatment with first- and second-generation EGFR TKIs, how about the later stages? 4. The introduction is disordered, and Introduction should also briefly mention the purpose of the review. 5.

New insights should be more detail, and I think this part is vital. List the points are better. 6. The current obstruction for treating EGFR-mutated NSCLC also should be discussed.